Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1999-10-06
2002-09-17
Chin, Christopher L. (Department: 1641)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S300000, C530S350000, C530S395000, C530S388800, C530S391100, C530S391300, C530S391500, C530S391700, C530S391900, C514S002600, C514S012200, C514S387000, C435S069600, C435S188500, C435S287100, C435S289100, C435S817000, C435S091500, C435S007100, C435S317100, C435S091500, C435S091500, C435S006120, C435S912000, C435S005000, C435S007900, C435S176000, C435S007930, C435S007940, C435S288200, C435S291400, C424S001490, C424S001410, C424S001450, C424S001690, C424S009362, C424S164100, C424S085100, C424S078080, C424S
Reexamination Certificate
active
06451980
ABSTRACT:
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
BACKGROUND OF THE INVENTION
An immunoassay utilizes antibodies to detect a compound of choice. However, the sensitivity of this detection is generally limited to the amount of signal that can be carried either on an antibody, for a direct binding assay, or on the probe compound, in a competitive inhibition assay. For example, in existing immunoassays, such as radioimmunoassays, ELISA, immunofluorescent assays or immunochemiluminescent assays, too many signal entities, such as radioisotopes, horse radish peroxidase or alkaline phosphatase, attached to the detection moieties invariably inactivate the antibody or denature the antigen and change the property of he detection probe. Therefore, in order to obtain more signal, additional antibody or probe must be added. This, in turn, reduces the sensitivity of the assay, the capability of the assay to detect minute quantities of the compound in question.
For all existing immunoassays, there is lag time for the compound of interest to reach a high enough concentration in the serum to become detectable for diagnostic purposes. In the case of heart attacks, there is a delay of 4-6 hours from the onset of chest pain until the diagnostic detection of CK-MB, Troponin-T or I is possible. Myoglobin is detectable earlier, but its specificity is low. If there were an assay that could detect very minute increases of these indicator compounds in the blood at an earlier point in time, then therapeutic intervention could be started earlier and thereby bring about greater myocardial salvage. In the case of cancer detection, where, e.g., tumor associated antigens related to breast cancer or colon cancer, etc., are detected, treatment might be more effective if minute elevations of these antigens could be detected at an early stage. Therefore, there is a need to increase the sensitivity of the assay without adversely affecting the specificity of the assay system.
SUMMARY OF THE INVENTION
The invention is directed to a method to increase the sensitivity of an immunoassay, by at least 10,000 fold, without losing specificity. This improvement is achieved by the use of a bispecific antibody complex and a unique detection signal probe capable of recognizing the bispecific antibody complex.
In one aspect, the invention features an immunoassay method including reacting a sample from a patient with a bispecific antibody, wherein the bispecific antibody includes one antibody specific for a compound to be detected and a second antibody specific for a compound foreign to said patient sample, i.e., non-endogenous, and subsequently reacting the patient sample with a polymer probe, wherein the polymer probe includes a compound recognized by the second antibody in the bispecific antibody complex and further includes at least two detectable signals. The invention also features the bispecific antibody and the polymer probe of the method of the invention. Preferably, the sample from the patient is a blood or serum sample; the bispecific antibody includes an antimyosin antibody and an antibody against DTPA; and the polymer probe is a polylysine polymer and includes DTPA and at least six HRP as the detectable signal compounds.
REFERENCES:
patent: 5223242 (1993-06-01), Khaw et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5482698 (1996-01-01), Griffiths
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5698178 (1997-12-01), Goldenberg
patent: 5851527 (1998-12-01), Hansen
patent: WO 90/15993 (1990-12-01), None
patent: WO 94/12196 (1994-06-01), None
Torchilin, V.p., et al. The antibody linked chelating polymers for nuclear therapy and diagnostics. Crit. rev. Therap. drug Carrire Syst. 1991., vol. 7, No. 4, pp. 275-308. Abstract Only.*
Torchilin et al., “The antibody linked chelating polymers for nuclear therapy and diagnostics”, Crit. Rev. Therap. Drug Carrier Syst., 7 No. 4, 275-308 (1991). These references were transmitted by the International Bureau.
Rosebrough, S.F., “Two step immunological approaches for imaging and therapy”, Q.J. Nucl. Med., 40 234-251 (1996). These references were transmitted by the International Bureau.
Vuillez et al., “Two-step immunoscintigraphy for non-small cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer”, J. Nuc. Med., 38 No. 4, 507-511 (1997). These references were transmitted by the International Bureau.
Kranenborg et al., “Development and Characterization of anti-renal cell carcinoma X antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma”, Canc. Res. 55, 23 Supplement 5864s-5867s (1995). These references were transmitted by the International Bureau.
Devys et al., “Comparative targeting of human colon-carcinoma multi-cell spheroids using one-and two-step (bispecific antibody) techniques”, Int. J. Cancer, 67 883-891 (1996). These references were transmitted by the International Bureau.
Khaw Ban-an
Narula Jagat
Ban-An Khaw
Chin Christopher L.
Daniels-Cook Lisa V
LandOfFree
Signal enhancement of bispecific antibody-polymer probe for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Signal enhancement of bispecific antibody-polymer probe for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Signal enhancement of bispecific antibody-polymer probe for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2899250